Get ready to mark your calendars because NRx Pharmaceuticals (NASDAQ: NRXP) and its subsidiary, HOPE Therapeutics, are about to take center stage at the prestigious Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th.
Dr. Jonathan Javitt, the driving force behind both companies, will be delivering a highly anticipated company update, offering a deep dive into their groundbreaking work in central nervous system disorders.
But this isn’t just another corporate presentation.
NRx Pharmaceuticals is on a mission to revolutionize the treatment of conditions like suicidal bipolar depression, chronic pain, and PTSD.
They’re pioneering therapeutics built on their innovative NMDA platform, and their lead candidate, NRX-101, has already earned FDA Breakthrough Therapy designation for its potential in treating suicidal treatment-resistant bipolar depression and chronic pain.
The company plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia.
If you’re eager to catch Dr. Javitt’s presentation live, tune in to the webcast on the NRX Events section of their Investor Relations website at 9:20 AM EST. Don’t worry if you miss it – a replay will be available for 30 days.
Beyond the Oppenheimer Conference, the team will also be hitting the ground running at the BIO CEO & Investor Conference in New York from February 10th to 12th, actively seeking collaborations and partnerships.
And that’s not all! Before the Oppenheimer event, Dr. Javitt and Dr. David Feifel will be headlining the 8th Annual Neuroscience Innovation Forum in San Francisco.
Their keynote, “Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD,” promises to be a thought-provoking exploration of how cutting-edge therapies like Transcranial Magnetic Stimulation and Digital Therapeutics can be integrated with NMDA-targeted drug therapy.
Why this matters:
NRx Pharmaceuticals, along with HOPE Therapeutics, are not simply developing new drugs; they’re actively shaping the future of mental healthcare.
Their focus on innovative approaches, like NMDA-targeted therapies and the integration of interventional psychiatry clinics (through HOPE Therapeutics’ planned acquisitions), signals a paradigm shift in how we approach these complex conditions.
Also Read
Top Pharma Logistics Software to Streamline Your Operations
Top pharma Companies That Make Ozempic and Similar GLP-1 Medications
When manufacturing and supply chain professionals gather in Atlanta from April 13-16, 2026, they'll experience…
Munich, January 29, 2026 – Intralogistics is undergoing a quiet but profound transformation. What was…
SPAR South Africa is facing a massive R168.7 million lawsuit filed in the Durban High…
The South African Social Security Agency (SASSA) has issued an important public notice regarding the…
The South African Social Security Agency (SASSA) has officially released the grant payment schedule for…
The U.S. economy added just 50,000 jobs in December 2025, capping a year of dramatic…